Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOL1 | O14791 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Inaxaplin SCHEMBL22118438 | 1.00 | APOL1 (1.00) | APOL1 | |
| Inaxaplin SCHEMBL22118376 | 1.00 | APOL1 (1.00) | APOL1 | |
| Inaxaplin SCHEMBL31006383 | 1.00 | APOL1 (1.00) | APOL1 | |
| Inaxaplin SCHEMBL30218294 | 1.00 | APOL1 (1.00) | APOL1 | |
| Inaxaplin SCHEMBL22161355 | 1.00 | APOL1 (1.00) | APOL1 | |
| Inaxaplin SCHEMBL22118436 | 1.00 | APOL1 (1.00) | APOL1 | |
| Inaxaplin SCHEMBL22118384 | 1.00 | APOL1 (1.00) | APOL1 | |
| SCHEMBL22160137 | 0.94 | APOL1 (0.89) | APOL1 | |
| SCHEMBL22160042 | 0.94 | APOL1 (0.88) | APOL1 | |
| SCHEMBL22160056 | 0.94 | APOL1 (0.88) | APOL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897833-B1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2026-02-04 | — | — | EP | disclosed |
| CN-115209894-B | Methods of treating APOL-1 dependent focal segmental glomerulosclerosis | 弗特克斯药品有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20240277661-A1 | METHODS OF TREATING APOL-1 DEPENDENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS | VERTEX PHARMA (US) | 2024-08-22 | — | — | US | disclosed |
| CN-113453760-B | APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4165023-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | Vertex Pharmaceuticals Incorporated (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-4165036-A1 | SOLID FORMS OF APOL1 INHIBITOR AND USING THE SAME | Vertex Pharmaceuticals Incorporated (US) | 2023-04-19 | — | — | EP | disclosed |
| CN-115867543-A | Solid forms of an APOL1 inhibitor and methods of use thereof | 弗特克斯药品有限公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-4114385-A1 | METHODS OF TREATING APOL-1 DEPENDENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS | Vertex Pharmaceuticals Incorporated (US) | 2023-01-11 | — | — | EP | disclosed |
| CN-115209894-A | Method for treating APOL-1 dependent focal segmental glomerulosclerosis | 弗特克斯药品有限公司 | 2022-10-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277661-A1 | METHODS OF TREATING APOL-1 DEPENDENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS | APOL1, APOB, NPC1L1 | APOL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.